• 1
    Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:73655.
  • 2
    Grunewald J, Wahlstrom J, Berlin M, Wigzell H, Eklund A, Olerup O. Lung restricted T cell receptor AV2S3+ CD4+ T cell expansions in sarcoidosis patients with a shared HLA-DRbeta chain conformation. Thorax 2002; 57:34852.
  • 3
    Grunewald J, Olerup O, Persson U, Ohrn MB, Wigzell H, Eklund A. T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci USA 1994; 91:49659.
  • 4
    Grunewald J, Berlin M, Olerup O, Eklund A. Lung T-helper cells expressing T-cell receptor AV2S3 associate with clinical features of pulmonary sarcoidosis. Am J Respir Crit Care Med 2000; 161:81418.
  • 5
    Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156:16015.
  • 6
    Idali F, Wiken M, Wahlstrom J et al. Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis. Eur Respir J 2006; 27:4519.
  • 7
    Miyara M, Amoura Z, Parizot C et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med 2006; 203:35970.
  • 8
    Planck A, Katchar K, Eklund A, Gripenback S, Grunewald J. T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:11017.
  • 9
    Shevach E. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389400.
  • 10
    Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:3306.
  • 11
    Venken K, Hellings N, Hensen K et al. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J Neurosci Res 2006; 83:143246.
  • 12
    Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes MF, Rebelo M, Demengeot J. Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci USA 2005; 102:40916.
  • 13
    Sebastiani S, Allavena P, Albanesi C et al. Chemokine receptor expression and function in CD4+ T lymphocytes with regulatory activity. J Immunol 2001; 166:9961002.
  • 14
    Bruhl H, Cihak J, Schneider MA et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol 2004; 172:8908.
  • 15
    Veillard NR, Steffens S, Pelli G et al. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation 2005; 112:8708.
  • 16
    Huang B, Lei Z, Zhao J et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007; 252:8692.
  • 17
    Zissel G, Homolka J, Schlaak J, Schlaak M, Muller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 154:71319.
  • 18
    Minshall EM, Tsicopoulos A, Yasruel Z et al. Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. Eur Respir J 1997; 10:20349.
  • 19
    Oltmanns U, Schmidt B, Hoernig S, Witt C, John M. Increased spontaneous interleukin-10 release from alveolar macrophages in active pulmonary sarcoidosis. Exp Lung Res 2003; 29:31528.
  • 20
    Eklund A, Blaschke E. Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis. Thorax 1986; 41:62934.
  • 21
    Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39:22535.
  • 22
    Hartl D, Koller BT, Mehlhorn A et al. Quantitative and functional impairment of pulmonary CD4+CD25hi regulatory T cells in pediatric asthma. Basic Clin Immun 2007; 119:125866.
  • 23
    Roncador G, Brown PJ, Maestre L et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005; 35:168191.
  • 24
    Kasprowicz D, Droin N, Soper D, Ramsdell F, Green D, Ziegler S. Dynamic regulation of FoxP3 expression controls the balance between CD4+ T cell activation and cell death. Eur J Immunol 2005; 35:342432.
  • 25
    Ehrenstein MR, Evans JG, Singh A et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF therapy. JEM 2004; 200:27785.
  • 26
    Balandina A, Lecart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4(+) CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005; 105:73541.
  • 27
    Huan J, Culbertson N, Spencer L et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005; 81:4552.
  • 28
    Lopes JE, Soper DM, Ziegler SF. Foxp3 is required throughout the life of a regulatory T cell. Sci STKE 2007; 893:36.
  • 29
    Xu G, Mou Z, Jiang H et al. A possible role of CD4+CD25+ T cells as well as transcription factor Foxp3 in the dysregulation of allergic rhinitis. Laryngoscope 2007; 117:87680.
  • 30
    Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108:25361.
  • 31
    Zheng L, Teschler H, Guzman J, Hubner K, Striz I, Costabel U. Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med 1995; 152:10616.
  • 32
    Myatt N, Coghill G, Morrison K, Jones D, Cree IA. Detection of tumour necrosis factor alpha in sarcoidosis and tuberculosis granulomas using in situ hybridisation. J Clin Pathol 1994; 47:4236.
  • 33
    Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006; 100:20539.
  • 34
    Karagiannidis C, Akdis M, Holopainen P et al. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114:142533.
  • 35
    Katchar K, Wahlstrom J, Eklund A, Grunewald J. Highly activated T-cell receptor AV2S3(+) CD4(+) lung T-cell expansions in pulmonary sarcoidosis. Am J Respir Crit Care Med 2001; 163:15405.
  • 36
    Grunewald J, Wigzell H. T-cell expansions in healthy individuals. Immunologist 1996; 4:99103.